Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression

Dimitrios Panutsopulos†1, Alexandros Zafiropoulos†1, Elias Krambovitis2, George E Kochiadakis3, Nikos E Igoumenidis3 and Demetrios A Spandidos*1

Address: 1Laboratory of Virology, Medical School, University of Crete, Heraklion, Crete, Greece, 2Department of Applied Biochemistry & Immunology, Institute of Molecular Biology & Biotechnology, Vassilika Vouton, Heraklion, Crete, Greece and 3Cardiology Department, University Hospital of Heraklion, Crete, Greece

Email: Dimitrios Panutsopulos - panutsop@med.uoc.gr; Alexandros Zafiropoulos - zafeiros@med.uoc.gr; Elias Krambovitis - krambo@imbb.forth.gr; George E Kochiadakis - cardiol@med.uoc.gr; Nikos E Igoumenidis - cardiol@med.uoc.gr; Demetrios A Spandidos* - spandidos@spandidos.gr

* Corresponding author †Equal contributors

Abstract

Background: Macrophages can produce vascular endothelial growth factor (VEGF) in response to hypoxia, transforming growth factor β1 (TGF-β1), angiotensin II, basic fibroblast growth factor (bFGF), and interleukin-1. These factors have been found in the serum of coronary artery disease (CAD) patients as well as in atherosclerotic lesions. The aim of the present study was to test the hypothesis that the expression of VEGF, TGF-β1 and bFGF in peripheral monocytes and lymphocytes is related to CAD.

Methods: Human Mononuclear cells and lymphocytes from peripheral blood were isolated from 53 donors undergoing angiography. Seventeen were found to be healthy and 36 were diagnosed with CAD. The respective mRNAs were extracted and quantified.

Results: The statistical analysis revealed a significant increase of the basal level expression for macrophage VEGF and bFGF in the CAD SA (stable angina) patient group compared to the noCAD (control) (p = 0.041 and p = 0.022 respectively) and CAD UA (unstable angina) (p = 0.024 and p = 0.005 respectively) groups, which was highly dependent on the diabetic status of the population. Furthermore, we demonstrated with an in vitro cell culture model that the levels of VEGF and bFGF in monocytes of healthy donors are not affected by short term exposure to increased glucose levels (usually observed in the diabetic patients) and/or statin.

Conclusion: Our findings display a statistically significant association of the increased VEGF and bFGF levels in peripheral monocytes, with stable angina and diabetes in coronary artery disease. The results give new insight to CAD and the impaired collateral vessel formation in diabetics.
the initiation and progression of atheroma formation. The differentiation state of macrophages is directly related to macrophage metabolism of lipoproteins and cholesterol and consequently foam cell formation [2]. Progression of atherosclerosis relates to accumulation of macrophages, alteration of EC (endothelial cell) function, phenotypic modulation of SMCs (smooth muscle cell), and neovascularization of the plaque tissue [3,4].

A secondary to atherosclerosis event, also involving macrophages, is the process of collateral vessel development (arteriogenesis) which appears under hypoxic stress [5]. Arteriogenesis is beneficial to patients with CAD (coronary artery disease) where stenosis or occlusion causes repetitive or chronic regional myocardial ischemia [6]. Following the occlusion of a large artery, the stress of ischemia causes nearby arterioles to become activated. Their endothelial surface upregulates expression of adhesion molecules [7] and triggers the initial monocyte invasion into the arterial wall of the growing collateral arteriole. The proposed model [8] states that the infiltrating monocytes/macrophages produce VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor) and other factors which act on both the endothelium and the smooth muscle cells thereby inducing more VEGF production from these cells. Additional migration of monocytes is facilitated by the secretion of several growth factors including VEGF, bFGF and MCP-1 (monocyte chemotactic protein 1). Arteriogenesis has been shown to vary between individuals [9] and it was defective in diabetic individuals where the migratory response of monocytes/macrophages produce VEGF was attenuated [10].

Modified low density lipoproteins, proinflammatory cytokines and chemotactic factors are known to affect the differentiation and migration status of macrophages and thus play a role in the macrophage mediated atherogenesis in the vascular wall [3] and collateral vessel formation [8]. Macrophages can produce VEGF in response to hypoxia, TGF-β1, angiotensin II, bFGF, and interleukin-1 [11,12]. These factors have also been found to be expressed in atherosclerotic lesions.

CAD patients receive standard medication which among other compounds includes statins. HMG-CoA reductase inhibition by statins as established drugs for the treatment of hypercholesterolaemia [13] has been associated with beneficial effects on the progression and regression of atherosclerosis in humans and in animal models [14,15]. Statins have been reported to influence the surface phenotype of peripheral lymphocytes [16].

Atherogenesis is believed to be a system-wide inflammatory response. As such, all peripheral lymphocytes and monocytes could be affected. Although VEGF, bFGF and TGF-β1 are involved in the mechanism of atherogenesis and collateral vessel development, a detailed analysis of the steady state mRNA levels of these factors in isolated peripheral monocyte and lymphocyte populations of patients with CAD has not been previously performed. The aim of the present study was to test the hypothesis that the expression levels of VEGF, TGF-β1 and bFGF in peripheral monocytes and lymphocytes is related to CAD. We also tested the effect of clinical parameters related to CAD (diabetes, type of myocardial ischemic episodes) on the above relationship. The strategy involved exploring the expression levels of VEGF, TGF-β1 and bFGF in purified peripheral monocytes and lymphocytes from patients with CAD and normal donors. We observed a significant increase of VEGF and bFGF but not TGF-β1 in CAD patients with stable angina, which is even more pronounced in the diabetics. Furthermore we demonstrated with an in vitro cell culture model that the short term effect of glucose and/or statins, which are usually observed in the diabetic CAD patients, did not increase the levels of VEGF and bFGF on monocytes from healthy donors.

**Methods**

**Patients**

Patients were recruited randomly from those undergoing diagnostic catheterization at the University Hospital (Heraklion, Crete, Greece) over a 4 month period. A total of 53 patients were included in the study. A group of 36 patients, that were submitted to angiography due to angina pectoris, showed ≥ 1 vessel coronary stenosis of ≥ 70% by visual analysis and thus were considered as CAD group. A total of 17 individuals, that were submitted to angiography due to valvular disease or nontypical chest pain syndrome with a negative or non diagnostic exercise ECG or asymptomatic episodes of unsustained ventricular tachycardia, were found to have no stenosis and were considered to be the control group (noCAD). Due to poor RNA yields we excluded from the analysis 4 macrophage (1 CAD UA, 2 noCAD and 1 CAD SA) and 12 lymphocyte samples (5 CAD UA, 3 noCAD and 4 CAD SA).

The patients, and controls had no evidence of peripheral artery or cerebrovascular disease; all had normal echo-duplex of cervical arteries, the aorta and lower limb arteries and/or resting and post-exercise ankle/brachial pressure index > 0.85. Criteria for exclusion were 1) age < 18.2) clinical or laboratory signs of acute or chronic inflammatory disease and 3) presence of overt neoplastic disease.

The definitions of the clinical parameters used in the study are presented below. A. Hypertension: systolic blood pressure ≥ 160 mm Mg and or diastolic > 90 mm Mg. B. Hypercholesterolaemia: LDL ≥ 160 mg/dl for patient without any artery risk factors for coronary artery
and incubated in a 5% CO2 incubator (Forma) at 37°C for 1 hour to allow for monocyte attachment. The non adherent cells were removed by washing twice with PBS and new RPMI1640 medium was added containing 5% human serum. Fluvastatin (1 μM) or glucose (6 mg/ml) was added according to the study design. At an appropriate time period (30 min, 1 h, 2 h, 4 h, 24 h, 48 h) cells were harvested and mRNA was extracted and purified.

**Extraction and quantification of mRNA**

Total RNA was isolated directly from the tissue culture dishes containing the adherent monocytes using the Trizol reagent (Life Technologies Ltd., U.K.). Briefly, 1 ml of reagent was added to each dish with vigorous pipetting and transferred to a 1.5 ml Eppendorf tube. Chloroform (200 μl) was added, and the tube was vortexed and centrifuged at 14 000 rpm for 15 minutes. The RNA was precipitated with an equal volume of isopropanol and washed with 75% ethanol. The RNA was air-dried and suspended in water treated with diethyl pyrocarbonate. The RNA preparation was treated with DNase I to remove residual traces of DNA, purified with the phenol-Chloroform method and precipitated with ethanol. The non-adherent/lymph fraction was harvested, centrifuged and RNA extraction was performed with the Trizol reagent according to the manufacturer’s instructions. RNA concentration and purity was determined on a UV spectrophotometer (Hitachi Instruments Inc., U.S.A.) by the 260 nm absorbance and 260 nm to 280 nm absorbance ratio respectively. 1% agarose gel electrophoresis and ethidium bromide staining were used to examine RNA integrity.

**Semi-quantitative RT-PCR**

Each quantification set included two PCR reactions (the target and the β2-microglobulin (β2M) reference). Each PCR reaction (target and β2M) was optimized individually for primer, Mg and Taq polymerase concentration using as a template a representative pool of all samples to be measured. Then the reactions were combined into a single tube in order to eliminate tube to tube variations. A new optimization was performed to ensure that there was no cross inhibition between the two PCR reactions. Subsequently another optimization was performed modulating the relative concentration of the two sets of primers to ensure that the two reactions reached the logarithmic phase of expansion in the same PCR cycles (reaction synchronization). Finally we determined the cycle in which the reaction reached the middle of the logarithmic expansion phase. The set of conditions that were established regarding primer, Mg, Taq polymerase concentration and cycle number, was applied specifically to the set of samples that were used for the standardization (sample pool).
and the corresponding target. The total standardization procedure was repeated for each quantification reaction (bFGF, VEGF, TGF-β1).

Reverse transcription reactions for the preparation of first strand cDNA from 1 μg of total RNA, were performed for 1 h at 52°C, using 15 U Thermoscript reverse transcriptase, 40 U RNaseOut, 50 ng of random hexamers and 1.0 mM of each dNTP in a total volume of 20 µl of 1x First Strand cDNA Synthesis Buffer containing 5 mM dithiothreitol (DTT), ensued by incubation for 20 min at 37°C with 2 U of E. coli RNaseH to avoid RNA contamination of cDNA, according to the manufacturer's protocol (Life Technologies Ltd., U.K.).

PCR assays were carried out in a PTC-200 programmable thermal controller (MJ Research Inc., U.S.A.); 1 µl of cDNA was amplified in a total volume of 10 µl containing the general PCR protocol included 1x PCR reaction buffer, 2.5 mM MgCl2, 0.4 mM dNTPs, and 0.6 U Platinum Taq DNA polymerase (Life Technologies Ltd., U.K.), with 30 pmol of each primer set. Cycling parameters were as follows: 3 min for initial denaturation at 94°C; 30 sec at 94°C, 30 sec at 58°C for primer annealing, 40 sec at 72°C for primer extension, these steps were repeated for 35 cycles; final extension step at 72°C for 10 min. β2-microglobulin was used as an internal control in all PCR reactions.

PCR products were analysed by 8% polyacrylamide gel electrophoresis (29:1 ratio acrylamide/bis-acrylamide) and silver stained. Gels were scanned on an Agfa Snap-Scan 1212 u (Agfa-Gevaert N.V., Belgium). The integrated density of the bands was used as quantitative parameter and was calculated by digital image analysis (Scion image). The ratio of the integrated density of each gene divided by that of β2-microglobulin was used to quantify the results.

The oligonucleotide primers used in the study were: β2-microglobulin;Forward (F): TCCAACATCAACATCCTTGTT; β2-microglobulin;Reverse (R): TCCCCCAAATTCTAAGCAGA, TGF-β1;F: ATGAACTCATCAGTACCATAGC, TGF-β1;R: CTATCCCCCATAAAGCAGG, VEGF;F: ACGATCGATACAGAAACCACG, VEGF;R: CTCCTCGCCAGAGTCTCCCT, bFGF;F: GCCACATCTAATCTCAATTCACA, bFGF;R: CTGGGTAACAGCAGATGCAA.

Statistical analysis
Data are reported as mean ± SEM. Initial statistical comparison of the mRNA expression results between the CAD and the noCAD (control) groups was performed utilizing the Mann Whitney test [18]. Subsequent analysis between noCAD, CAD SA (stable angina) and CAD UA (unstable angina) groups for statistically significant differences in quantitative data was performed with the use of the X2 test. Analysis between groups for continuous variables such as age, number of diseased vessels and % of lymphocytes was performed with one-way ANOVA. The expression of VEGF, bFGF and TGF-β1 mRNA was compared between the groups noCAD, CAD SA (stable angina) and CAD UA (unstable angina) by ANCOVA with age, number of diseased vessels, family history of heart disease, diabetes, smoking, hypertension, and hypercholesterolaemia as covariates. Bonferroni post hoc comparisons were performed to compare the adjusted levels of VEGF, bFGF and TGF-β1 between the 3 groups.

Results
Quantitation of the mRNA for VEGF, bFGF and TGF-β1 in peripheral monocytes and lymphocytes
A representative semi-quantitative RT-PCR assay demonstrating a range of differences in the production of VEGF, bFGF and TGF-β1 mRNA in 5 different donors is shown in Figure 1. The quantification and statistical evaluation of the mRNA expression results (Mann Whitney test) for the CAD and the noCAD (control) groups showed no significant difference for any of the above factors. Stepwise regression analysis of the expression of VEGF with CAD-related clinical parameters (angina, age, number of diseased vessels, family history of heart disease, diabetes, smoking, hypertension, and hypercholesterolaemia) revealed a highly significant association to the angina parameter (R = 0.5, p = 0.003).

In order to investigate further the relation of the mRNA expression of VEGF, bFGF and TGF-β1 with the angina parameter we divided our patients in the following groups: noCAD (control), CAD SA (CAD with stable angina), CAD UA (CAD with unstable angina) and proceeded with the statistical evaluation alone or in cooperation with other clinical parameters. The profile of the donors in the noCAD, CAD SA and CAD UA groups with regard to sex, levels of uric acid, hypertension, cigarette smoking, diabetes, family history, hypercholesterolaemia and number of diseased vessels is given in Table 1. Lymphocyte counts for the donors are shown in Table 2. There was no statistically significant difference between the 3 patient groups in any of these variables.
The statistical analysis of the mRNA quantification results revealed a significant difference in the basal level expression between the three patient groups for macrophage VEGF and bFGF. No statistically significant differences were detected for macrophage TGF-β and lymphocyte VEGF, bFGF and TGF-β.

A summary of the results is shown in Table 3. In peripheral macrophages for donors with no coronary arterial disease (noCAD) the mean VEGF/β2M ratio was 32.13+/−8.38, for CAD patients with stable angina the mean VEGF/β2M ratio was 152.07+/−50.63 and for CAD patients with unstable angina the mean VEGF/β2M ratio was 23.86+/−6.7. The respective mean values of bFGF/β2M ratio in the above patient groups were: noCAD 4.31+/−3.72, CAD SA 22.66+/−14.16 and CAD UA 1.62+/−1.62.

The statistical analysis of the mRNA quantification results revealed a significant difference in the basal level expression between the three patient groups for macrophage VEGF and bFGF. No statistically significant differences were detected for macrophage TGF-β and lymphocyte VEGF, bFGF and TGF-β.

A summary of the results is shown in Table 3. In peripheral macrophages for donors with no coronary arterial disease (noCAD) the mean VEGF/β2M ratio was 32.13+/−8.38, for CAD patients with stable angina the mean VEGF/β2M ratio was 152.07+/−50.63 and for CAD patients with unstable angina the mean VEGF/β2M ratio was 23.86+/−6.7. The respective mean values of bFGF/β2M ratio in the above patient groups were: noCAD 4.31+/−3.72, CAD SA 22.66+/−14.16 and CAD UA 1.62+/−1.62.

The statistical analysis of the mRNA quantification results revealed a significant difference in the basal level expression between the three patient groups for macrophage VEGF and bFGF. No statistically significant differences were detected for macrophage TGF-β and lymphocyte VEGF, bFGF and TGF-β.

A summary of the results is shown in Table 3. In peripheral macrophages for donors with no coronary arterial disease (noCAD) the mean VEGF/β2M ratio was 32.13+/−8.38, for CAD patients with stable angina the mean VEGF/β2M ratio was 152.07+/−50.63 and for CAD patients with unstable angina the mean VEGF/β2M ratio was 23.86+/−6.7. The respective mean values of bFGF/β2M ratio in the above patient groups were: noCAD 4.31+/−3.72, CAD SA 22.66+/−14.16 and CAD UA 1.62+/−1.62.
The effect of glucose and statins in the expression of VEGF and bFGF

We selected 2 independent healthy male donors, age of 27 and 23 years, with no prior history of atherosclerosis or diabetes. These samples were processed in an identical fashion to those from patients from the catheterization laboratory. The intra assay variability of the mRNA measurements of our in vitro short term culture system was assessed by measuring the VEGF and bFGF mRNA in triplicate cultures each. For donor 1 the mean VEGF/bFGF ratio was 97.5+/-1.53 and bFGF/β2M ratio 18.87+/-2.37. For donor 2 the mean VEGF/bFGF ratio was 45.47+/-4.55 and bFGF/β2M ratio 18.87+/-2.37.

Furthermore we analyzed in the above model the effect of high glucose levels found in diabetic individuals and statins found in the medication of all our patients on the mRNA levels of VEGF and bFGF during a 48 hour period. We isolated a blood sample from healthy donor 1 in an identical fashion to those from patients from the catheterization laboratory and set cultures with appropriate concentrations of glucose, statin and glucose+statin. After the 1 hour attachment period the cultures were harvested at specific time intervals (30 min, 1 h, 2, 4, 24 h, 48 h) and the mRNA of VEGF and bFGF was quantified. The results show a gradual time dependent decrease of both mRNA levels (Figure 2) which was not affected by glucose or statin. The experiment was repeated with a different donor and the results were similar. Although the initial values of bFGF and VEGF differed slightly, consistent with the donor variation, the trend for decline of expression was the same. These results should be evaluated in the context of our in vitro system since in vivo gene expression is not always the same.

Statistical evaluation of the results between different patient groups

The mRNA quantification revealed a significant difference in the basal level expression between the three groups for macrophage VEGF and bFGF(Figure 3A,3C). No statistically significant differences were detected for macrophage TGF-β1 and lymphocyte VEGF, bFGF and TGF-β1.

The difference in the macrophage VEGF expression between noCAD control patients and CAD SA patients was statistically significant (p = 0.041), as was the difference between patients with CAD SA and CAD UA (p = 0.024) (Figure 3A). There was no statistical difference between the macrophage VEGF expression of noCAD and CAD UA patients (p = 0.445) (Figure 3A). Similarly, for macrophage bFGF, the difference in expression between patients with CAD SA and CAD UA was highly statistically significant (p = 0.005) as was the difference between patients with CAD SA and noCAD (p = 0.022) (Figure 3C). There was no statistical difference between noCAD and CAD UA patients (p = 0.160) (Figure 3C). No statistically significant differences were detected for macrophage TGF-β1 and lymphocyte VEGF (Figure 3E), bFGF and TGF-β1 in any of the patient groups.

The mRNA expression data from the 3 groups were subjected to ANCOVA using the variables age, sex, prior myocardial infarction, hypertension, family history, hypercholesterolaemia, cigarette smoking, diabetes, and number of diseased vessels as covariates. The simple analysis of variance gave a significant difference between the three groups for macrophage VEGF (p = 0.011) (Figure 3B) and macrophage bFGF (p = 0.002) (Figure 3D). Diabetes was the only covariate found to influence greatly the variance improving considerably the significance of our model both for VEGF (p = 0.001) (Figure 3B) and bFGF (p = 0.000) (Figure 3D). Bonferroni post hoc comparison between the groups noCAD and CAD SA and between the groups CAD SA and CAD UA revealed a statistically significant difference in VEGF expression (p = 0.021 and p = 0.011 respectively). No significant difference was found between the groups with noCAD and CAD UA. Bonferroni post hoc comparison in bFGF expression between the groups CAD SA – CAD UA and noCAD – CAD SA revealed a statistically significant difference (p = 0.003) and (p = 0.016) respectively. No significant difference of bFGF was found between the groups noCAD – CAD UA (p = 0.843). Pearson two tailed correlation of VEGF and bFGF expression was found to be highly significant (p < 0.001).

Table 3: Summary of the results on VEGF and bFGF expression in monocytes (Mf) and lymphocytes (Ly)

|                  | No CAD     | CADSA      | CADUA     |
|------------------|------------|------------|------------|
| VEGF/β2M Mf      | 32.13+/-8.38 | 152.07+/-50.63 | 23.86+/-6.7 |
| bFGF/β2M Mf      | 16.73+/-8   | 85.98+/-25.26 | 5.3+/-1.63  |
| VEGF/β2M Ly      | 4.31+/-3.72 | 22.66+/-14.16 | 1.62+/-1.62 |

Data are presented as mean ± SEM (standard error of the mean). The values represent the VEGF/β2-microglobulin and bFGF/β2-microglobulin ratios which were calculated by the optical integrated density of each gene divided by that β2-microglobulin.
Discussion

The present study provides evidence on the relationship of the expression of VEGF, bFGF and TGF-β1 in the peripheral monocyte and lymphocyte cell populations from patients with coronary artery disease. The mRNA quantification revealed a significant increase of the basal level expression for macrophage VEGF and bFGF in the CAD SA patient group compared to the noCAD and CAD UA groups, which was highly dependent on the diabetic status of the population. Our findings contribute to the understanding of the role of VEGF, bFGF and TGF-β1 in cardiovascular disease.

A recent study on the hypoxic induction of VEGF reported a low level of VEGF expression from monocytes of atherosclerotic donors after 24 hours of culture [9]. Aiming to follow the kinetics of the mRNA expression of VEGF and bFGF during a 48 hour culture period we set up a control experiment with monocytes isolated from a healthy donor. We observed that the expression of both genes declined in a time dependent fashion reaching the lowest levels at 24 to 48 hours. The result explained the consistently low values reported previously [9]. Our measurements of the mRNA profile were performed immediately after cell isolation in order to ensure the representative mirroring of the in vivo condition. All samples were
Figure 3
Boxplots of the expression of VEGF and bFGF. Distribution boxplot of the expression of VEGF in monocytes/macrophages (A, B), bFGF in monocytes/macrophages (C, D) and VEGF in lymphocytes (E, F). The boxplots A, C and E demonstrate the expression in the control, CAD SA and CAD UA group. The boxplots B, D and F demonstrate the expression in the above groups classified for diabetes. The y-axis values represent the VEGF/β2-microglobulin and bFGF/β2-microglobulin ratios accordingly. The ratios were calculated by the optical integrated density of each gene divided by that of β2-microglobulin. The optical integrated density was calculated by digital image analysis (Scion image) of acrylamide gel electrophoresis of the RT-PCR products. Mf: macrophages, Ly: non-adherent lymphocyte fraction, ns: non-significant.
treated exactly the same way to ensure that the effect of cell handling and isolation, if any, was uniform.

All the patients in our study received standard medication which among other compounds included statins. Statins have been reported to influence the surface phenotype of peripheral lymphocytes [16]. To determine the effect of fluvastatin on the mRNA expression of bFGF and VEGF in monocytes of a healthy donor we performed kinetic analysis. We observed no significant effect on VEGF or bFGF during the 48 hour in vitro fluvastatin treatment. Glucose has been reported to be able to influence macrophage differentiation state in general and specifically CD36 through direct effect on the mRNA level [19]. Since our major finding is related to diabetic individuals usually exhibiting high glucose levels, we evaluated the short term effect of glucose on monocytes of a healthy donor similarly to the above kinetic analysis. We observed no significant deviation from the untreated mRNA levels for VEGF and bFGF during a 48 hour period after treatment with glucose alone or in combination with fluvastatin.

VEGF and bFGF have been isolated in human cardiac tissue where increased levels were observed among patients with acute myocardial infarction [20] and unstable angina pectoris [21]. Presence of VEGF and bFGF has been demonstrated in atherosclerotic lesions produced mainly by macrophages [22,23]. Furthermore it was reported that VEGF can induce migration and activation of monocytes through its receptor flt-1 [24], up regulation of adhesion molecules on endothelial cells [25] and secretion of monocyte chemoattractant protein 1 (MCP-1) [26].

Detection of VEGF in the serum in atherosclerotic patients requires the existence of an appropriate source producing it in high amount. Our results demonstrate that in CAD the VEGF, bFGF and TGF-β1 are not systematically produced by peripheral lymphocytes or monocytes. Expression of the VEGF and bFGF gene was restricted to the monocyte population in the CAD patient group with stable angina pectoris [21]. Presence of VEGF and bFGF has been demonstrated in atherosclerotic lesions produced mainly by macrophages [22,23]. Furthermore it was reported that VEGF can induce migration and activation of monocytes through its receptor flt-1 [24], up regulation of adhesion molecules on endothelial cells [25] and secretion of monocyte chemoattractant protein 1 (MCP-1) [26].

VEGF and bFGF have been isolated in human cardiac tissue where increased levels were observed among patients with acute myocardial infarction [20] and unstable angina pectoris [21]. Presence of VEGF and bFGF has been demonstrated in atherosclerotic lesions produced mainly by macrophages [22,23]. Furthermore it was reported that VEGF can induce migration and activation of monocytes through its receptor flt-1 [24], up regulation of adhesion molecules on endothelial cells [25] and secretion of monocyte chemoattractant protein 1 (MCP-1) [26].

Detection of VEGF in the serum in atherosclerotic patients requires the existence of an appropriate source producing it in high amount. Our results demonstrate that in CAD the VEGF, bFGF and TGF-β1 are not systematically produced by peripheral lymphocytes or monocytes. Expression of the VEGF and bFGF gene was restricted to the monocyte population in the CAD patient group with stable angina pectoris [21]. Presence of VEGF and bFGF has been demonstrated in atherosclerotic lesions produced mainly by macrophages [22,23]. Furthermore it was reported that VEGF can induce migration and activation of monocytes through its receptor flt-1 [24], up regulation of adhesion molecules on endothelial cells [25] and secretion of monocyte chemoattractant protein 1 (MCP-1) [26].

Collateral vessel formation termed arteriogenesis usually follows severe atherosclerosis. Arteriogenesis is severely reduced in patients with diabetes mellitus [35]. Recent studies showed that arteriogenesis requires active migration of peripheral monocytes to the site of ischemia and interaction with epithelium of the arteriole [8]. In addition it is known that the migration of monocytes is mediated through the action of VEGF and its receptor Flt-1 [36,37]. Trying to identify the molecular abnormality Waltenberger et al. demonstrated that in diabetics monocytes have a functional defect: they do not respond to migratory signals from VEGF although their Flt-1 receptor level is normal and the intracellular pathway is functional [10]. Our results demonstrate that monocytes from diabetic CAD SA patients express very high amounts of VEGF mRNA. We propose that the migratory defect could be caused by the increased autocrine VEGF production of the
References

1. Luis AJ: Atherosclerosis. Nature 2000, 407:233-241.
2. Krush HS: Macrophage foam cells and atherosclerosis. Front Biosci 2001, 6:D429-55.
3. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
4. O’Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB and Schwartz SM: Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994, 145:883-894.
5. Arras M, Ito WD, Scholz D, Winkler B, Schaper J and Schaper W: Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998, 101:40-50.
6. Piek JJ, van Liebergen RA, Koch KT, Peters RJ and David GK: Clinical, angiographic and hemodynamic predictors of recruitable collateral flow assessed during balloon angioplasty coronary occlusion. J Am Coll Cardiol 1997, 29:275-282.
7. Sampaio R, Kukielka GL, Smith CW, Eskin SG and McIntire LV: Shear stress-mediated changes in the expression of leukocyte adhesion receptors on human umbilical vein endothelial cells in vitro. Ann Biomed Eng 1995, 23:247-256.
8. Waltenberger J: Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001, 49:554-560.
9. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A and Levy AP: Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999, 100:547-552.
10. Watenberger J, Lange J and Kranz A: Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000, 102:185-190.
11. Ferrara N and Bunting S: Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 1996, 5:35-44.
12. Williams B, Baker AQ, Gallagher B and Lodwick D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995, 25:913-917.
13. Rij R and Rapaport E: Management of primary hyperlipidemia. N Engl J Med 1993, 329:1491-1498.
14. MAAS Investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344:633-638.
15. Zhu BQ, Siwers RE, Sun YP, Isenberg WM and Parmley WW: Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol 1992, 19:246-255.
16. Rothe G, Herr AS, Stohr J, Ableihouser C, Weidinger G and Schmitz G: A more mature phenotype of blood mononuclear phagocyte is induced by il-2 pretreatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 1999, 144:251-261.
17. Zafiriopoulos A, Baritaki S, Vlata Z, Spandidos DA and Krambouvis E: Dys-regulation of effector CD4+ T cell function by the V3 domain of the HIV-1 gp120 during antigen presentation. Biochim Biophys Acta 2001, 284:875-879.
18. Zar JH: Biostatistical Analysis 4th edition. Prentice Hall International; 1999:145-155.
19. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T and Asch AS: A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med 2001, 7:840-846.
20. Kumar S, West D, Shahabuddin S, Arnold F, Haboubi N, Reid H and Carr T: Angiogenesis factor from human myocardial infarcts. Lancet 1983, 2:364-368.
21. Cassells W, Speir E, Sasse J, Klagsbrun M, Allen P, Lee M, Calvo B, Chiba M, Haggroth L, Folkman J and et al.: Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest 1990, 85:433-441.
22. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Matsu K, Becker AE and Nakao K: Vascular endothelial growth factor expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998, 98:2108-2116.
23. Couffignal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes J and Isern JM: Vascular endothelial growth factor and vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997, 150:1673-1685.
24. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A and Marone D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF/VPF) is mediated via the VEGF receptor fct-1. Blood 1996, 87:3336-3343.
25. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS and Koh GY: Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001, 276:7614-7620.
26. Marumo T, Schini-Kerth VB and Busse R: Vascular endothelial growth factor activator nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999, 48:1311-1317.
27. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K and Fukuda N: Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 2000, 15:105-111.
28. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K and Fukuda N: Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 2000, 93:168-174.
29. Ogawa H, Suehiji H, Soejima H, Nishiyama K, Misumi K, Takazoe K, Miyamoto S, Kajiwara I, Sumida H, Sakamoto T, Yoshimura M, Kugiya K, Yasue H and Matsuo K: Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology 2000, 93:93-99.
30. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM and Gregor ZJ: Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996, 80:363-366.
31. Blann AD, Belgore FM, Constans J, Contri C and Lip GY: Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidaemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001, 87:1160-1163.
32. Belgore FM, Blann AD and Lip GY: Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci 2001, 100:567-575.
33. Blann AD, Belgore FM, McColman CN, Silverman S, Lip PL and Lip GY: Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci 2002, 102:187-194.
34. Dantz D, Bewersdorf J, Fruehwald-Schultes B, Kern W, Jelkmann W, Born J, Fehm HL and Peters A: Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia. J Clin Endocrinol Metab 2002, 87:835-840.
35. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H and Ergin A: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999, 99:2239-2242.
36. Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, Ishibashi M, Hiasa K, Ichiki T, Shibuya M and Takeshita A: Vascular endothelial growth factor is necessary in the development of atherosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002, 105:1110-1115.
37. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J and Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996, 271:17629-17634.